Cargando…
Combination therapy of rituximab and corticosteroids for patients with refractory chronic immune thrombocytopenic purpura: report of two cases
Immune thrombocytopenic purpura (ITP) is an autoimmune disorder, for which rituximab has been proven to be an effective treatment. The response rate was reported to be approximately 60% in refractory ITP patients. However, the response time is slower than expected, and the mechanism of action of rit...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Termedia Publishing House
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3685362/ https://www.ncbi.nlm.nih.gov/pubmed/23788996 http://dx.doi.org/10.5114/wo.2013.34629 |